Cancer biotech Instil Bio raises deal size by 25% ahead of $312 million IPO

Instil Bio, an early stage biotech developing immune cell therapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday.

The Dallas, TX-based company now plans to raise $312 million by offering 16 million shares at a price range of $19 to $20. The companyRead More